Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,369,729 papers from all fields of science
Search
Sign In
Create Free Account
LY 344864
Known as:
LY344864
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Carbazoles
Fluorobenzenes
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Symposium for Young Neuroscientists and Professors of the SouthEast
P. Kalivas
,
P. Kalivas
,
A. Romero-Sandoval
,
A. Alvarado
2016
Corpus ID: 34491315
Major and invasive surgeries are associated with a higher risk of developing chronic postoperative pain. We hypothesize that a…
Expand
2009
2009
Guinea pig hippocampal 5‐HT1E receptors: a tool for selective drug development
M. T. Klein
,
M. Teitler
Journal of Neurochemistry
2009
Corpus ID: 205620332
Recent studies have indicated that the serotonin [5‐hydroxytryptamine (5‐HT)] 1E receptor, originally discovered in human brain…
Expand
Review
2009
Review
2009
Serotonergic drugs have been instrumental tools in elucidat- ing the roles of serotonin [5-hydroxytryptamine (5-HT)] and its receptors in human physiology and pathology (Glennon
2009
Corpus ID: 115880945
Serotonergic drugs have been instrumental tools in elucidating the roles of serotonin [5-hydroxytryptamine (5-HT)] and its…
Expand
2003
2003
Pharmacological profile of the 5‐HT‐induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5‐HT1 and putative 5‐ht5A/5B receptors
A. Sánchez-López
,
D. Centurión
,
Erika Vázquez
,
U. Arulmani
,
P. Saxena
,
C. Villalón
British Journal of Pharmacology
2003
Corpus ID: 11806592
Continuous infusions of 5‐hydroxytryptamine (5‐HT) inhibit the tachycardiac responses to preganglionic (C7‐T1) sympathetic…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE